Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On June 6, 2023, the Company received written notice (the "Delisting Notice")
from the staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that,
as a result of the Company's filing for protection under Chapter 11 of the U.S.
Bankruptcy Code (the "Filing") and in accordance with Nasdaq Listing Rules 5101,
5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company's
common stock (the "Securities") will be delisted from Nasdaq. Trading of the
Securities will be suspended at the opening of business on June 15, 2023 and a
Form 25-NSE will be filed with the Securities and Exchange Commission, which
will remove the Company's securities from listing and registration on Nasdaq. In
the Delisting Notice, the staff of Nasdaq referenced concerns about the
Company's ability to sustain compliance with all requirements for continued
listing on Nasdaq, concerns regarding the residual equity interest of the
existing listed securities holders and public interest concerns related to the
Filing. The Company does not intend to appeal this determination.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
HTG MOLECULAR DIAGNOSTICS, INC. 
